Welcome!

News Feed Item

Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256137/Metachromatic-Leukodystrophy-MLD-Global-Clinical-Trials-Review-H2-2014.html

Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014" provides data on the Metachromatic Leukodystrophy (MLD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metachromatic Leukodystrophy (MLD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metachromatic Leukodystrophy (MLD). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Metachromatic Leukodystrophy (MLD) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Metachromatic Leukodystrophy (MLD) 24
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27

Prominent Sponsors 28
Top Companies Participating in Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Shire Plc 31
Clinical Trial Overview of Shire Plc 31
The Cooper Companies, Inc. 32
Clinical Trial Overview of The Cooper Companies, Inc. 32
GlaxoSmithKline plc 33
Clinical Trial Overview of GlaxoSmithKline plc 33
Cytomedix, Inc. 34
Clinical Trial Overview of Cytomedix, Inc. 34
Clinical Trial Overview of Top Institutes / Government 35
University of Louisville 35
Clinical Trial Overview of University of Louisville 35
IRCCS San Raffaele Milano 36
Clinical Trial Overview of IRCCS San Raffaele Milano 36

Fondazione San Raffaele del Monte Tabor 37
Clinical Trial Overview of Fondazione San Raffaele del Monte Tabor 37
University of Rostock 38
Clinical Trial Overview of University of Rostock 38
Fairview University Medical Center 39
Clinical Trial Overview of Fairview University Medical Center 39
New York Medical College 40
Clinical Trial Overview of New York Medical College 40
Masonic Cancer Center 41
Clinical Trial Overview of Masonic Cancer Center 41
Institut National de la Sante et de la Recherche Medicale 42
Clinical Trial Overview of Institut National de la Sante et de la Recherche Medicale 42
National Center for Research Resources 43
Clinical Trial Overview of National Center for Research Resources 43
Assistance Publique - Hopitaux de Paris 44
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 44
Five Key Clinical Profiles 45
Appendix 68
Abbreviations 68
Definitions 68
Research Methodology 69
Secondary Research 69
About GlobalData 70
Contact Us 70
Disclaimer 70
Source 70

List of Tables

Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16

Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Metachromatic Leukodystrophy (MLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23

Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Metachromatic Leukodystrophy (MLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Shire Plc, 2014* 31
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by The Cooper Companies, Inc., 2014* 32
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 33
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytomedix, Inc., 2014* 34
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Louisville, 2014* 35
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by IRCCS San Raffaele Milano, 2014* 36

Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fondazione San Raffaele del Monte Tabor, 2014* 37
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Rostock, 2014* 38
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fairview University Medical Center, 2014* 39
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by New York Medical College, 2014* 40
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2014* 41
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut National de la Sante et de la Recherche Medicale, 2014* 42
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Center for Research Resources, 2014* 43
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 44

List of Figures

Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15

Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Metachromatic Leukodystrophy (MLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Metachromatic Leukodystrophy (MLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 69

To order this report: Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256137/Metachromatic-Leukodystrophy-MLD-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Vulnerability management is vital for large companies that need to secure containers across thousands of hosts, but many struggle to understand how exposed they are when they discover a new high security vulnerability. In his session at 21st Cloud Expo, John Morello, CTO of Twistlock, addressed this pressing concern by introducing the concept of the “Vulnerability Risk Tree API,” which brings all the data together in a simple REST endpoint, allowing companies to easily grasp the severity of the ...
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...
In his session at 21st Cloud Expo, James Henry, Co-CEO/CTO of Calgary Scientific Inc., introduced you to the challenges, solutions and benefits of training AI systems to solve visual problems with an emphasis on improving AIs with continuous training in the field. He explored applications in several industries and discussed technologies that allow the deployment of advanced visualization solutions to the cloud.
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
"NetApp is known as a data management leader but we do a lot more than just data management on-prem with the data centers of our customers. We're also big in the hybrid cloud," explained Wes Talbert, Principal Architect at NetApp, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
"Infoblox does DNS, DHCP and IP address management for not only enterprise networks but cloud networks as well. Customers are looking for a single platform that can extend not only in their private enterprise environment but private cloud, public cloud, tracking all the IP space and everything that is going on in that environment," explained Steve Salo, Principal Systems Engineer at Infoblox, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventio...